A multitargeted treatment approach for anemia and cachexia in metastatic castration-resistant prostate cancer

Journal of Pain and Symptom Management

Volumn 50, Issue 2, 2015, Pages e1-e4

  MacCiò, Antonio ^a   Gramignano, Giulia ^b   Madeddu, Clelia ^c  

^a Ospedale Oncologico A Businco   (Italy)

^b Digestive Endoscopy Unit   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; CELECOXIB; CURCUMIN; FERRITIN; GONADORELIN DERIVATIVE; IRON; LACTOFERRIN; LEPTIN; PROSTATE SPECIFIC ANTIGEN; TASQUINIMOD;

AGED; ANEMIA; ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BONE SCINTISCANNING; CACHEXIA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURGERY; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC DISEASE; COMPUTER ASSISTED TOMOGRAPHY; EXHAUSTION; FERRITIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; LETTER; LYMPH NODE DISSECTION; MALE; NAUSEA; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION; ADENOCARCINOMA; COMPLICATION; PATHOPHYSIOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ADENOCARCINOMA; AGED; ANEMIA; CACHEXIA; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84938421284     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2015.04.014     Document Type: Letter

References (20)

1. N. Vogelzang One hundred thirteen men with hormone-refractory prostate cancer died today J Clin Oncol 14 1996 1753 1755
2. D.L. Suzman, and E.S. Antonarakis Castration-resistant prostate cancer: latest evidence and therapeutic implications Ther Adv Med Oncol 6 2014 167 179
3. K. Kuroda, J. Nakashima, K. Kanao, and et al. Interleukin 6 is associated with cachexia in patients with prostate cancer Urology 69 2007 113 117
4. R. Pili, M. Häggman, W.M. Stadler, and et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer J Clin Oncol 29 2011 4022 4028
5. N. Gupta, O. Al Ustwani, L. Shen, and R. Pili Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer Onco Targets Ther 7 2014 223 234
6. A. Macciò, C. Madeddu, G. Gramignano, and et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study Haematologica 100 2015 124 132
7. K. Fearon, F. Strasser, S.D. Anker, and et al. Definition and classification of cancer cachexia: an international consensus Lancet Oncol 12 2011 489 495
8. A. Macciò, C. Madeddu, G. Gramignano, and et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecologic cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life Gynecol Oncol 124 2012 417 425
9. G. Gramignano, M.R. Lusso, C. Madeddu, and et al. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy Nutrition 22 2006 136 145
10. G. Mantovani, A. Macciò, C. Madeddu, and et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia J Mol Med (Berl) 88 2010 85 92
11. Z. Culig Proinflammatory cytokine interleukin-6 in prostate carcinogenesis Am J Clin Exp Urol 2 2014 231 238
12. A. Macciò, C. Madeddu, G. Gramignano, and et al. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study Oncologist 15 2010 894 902
13. J.G. Nalesnik, A.G. Mysliwiec, and E. Canby-Hagino Anemia in men with advanced prostate cancer: incidence, etiology, and treatment Rev Urol 6 2004 1 4
14. D.A. Willie, M.A. Eisenberger, M.A. Carducci, and et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity Urology 45 1995 542 549
15. M. Sumitomo, M. Tachibana, J. Nakashima, and et al. An essential role for nuclear factor kB in preventing TNF-α-induced cell death in prostate cancer cells J Urol 161 1999 674 679
16. J.T. Isaacs The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer Expert Opin Investig Drugs 19 2010 1235 1243
17. E. Raymond, A. Dalgleish, J.E. Damber, M. Smith, and R. Pili Mechanisms of action of tasquinimod on the tumour microenvironment Cancer Chemother Pharmacol 73 2014 1 8
18. T. Tanno, A. Rabel, M. Alleyne, and et al. Hepcidin, anaemia, and prostate cancer BJU Int 107 2011 678 679
19. J. Bieniek, C. Childress, M.D. Swatski, and W. Yang COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins Prostate 74 2014 999 1011
20. C.M. Yin, J.H. Wong, J. Xia, and T.B. Ng Studies on anticancer activities of lactoferrin and lactoferricin Curr Protein Pept Sci 14 2013 492 503